Novartis Gene Therapies Releases SMA Community Statement

This week, Novartis Gene Therapies released an SMA community statement detailing the progress on enrollment for both STEER and STRENGTH clinical trials, their
investigational intrathecal (IT) OAV101 studies.

Check out the full letter here.


Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top